This week, we're again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We'll hear about findings in mesothelioma, small cell lung cancer, and drug development.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We'll hear about findings in mesothelioma, small cell lung cancer, and drug development.

This week, we're hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

This week, we're back for more coverage of the 2021 Gastrointestinal Cancers Symposium, hearing about the FIGHT trial in advanced gastric/gastroesophageal junction adenocarcinoma, the ClarIDHy study in IDH1-mutated cholangiocarcinoma, and the POLO trial in BRCA-mutated pancreatic cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're back for more coverage of the 2021 Gastrointestinal Cancers Symposium, hearing about the FIGHT trial in advanced gastric/gastroesophageal junction adenocarcinoma, the ClarIDHy study in IDH1-mutated cholangiocarcinoma, and the POLO trial in BRCA-mutated pancreatic cancer.

The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is being held this weekend, January 15th to 17th, 2021. We're discussing findings from the meeting with three study authors.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is being held this weekend, January 15th to 17th, 2021. We're discussing findings from the meeting with three study authors.

This week, we'll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We'll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

Coverage of stories discussed this week on ascopost.com:

Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We'll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

This week, we'll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We'll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

Coverage of stories discussed this week on ascopost.com:

Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We'll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

Coverage of stories discussed this week on ascopost.com:

Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

This week, we'll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We'll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

Coverage of stories discussed this week on ascopost.com:

Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

The San Antonio Breast Cancer Symposium took place virtually from December 8 to 12th. This week, we're featuring three important studies from the meeting, focusing on a new prognostic tool; the treatment of depression and related symptoms in young breast cancer survivors; and a chemoimmunotherapy regimen for triple-negative disease.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The San Antonio Breast Cancer Symposium took place virtually from December 8 to 12th. This week, we're featuring three important studies from the meeting, focusing on a new prognostic tool; the treatment of depression and related symptoms in young breast cancer survivors; and a chemoimmunotherapy regimen for triple-negative disease.

This week, we'll focus further on studies presented at the 2020 ASH Annual Meeting & Exposition, including findings on the use of whole-genome sequencing to trace the origins of a blood cancer; stem cell transplant for older patients with myelodysplastic syndromes; and a triplet therapy for relapsed and refractory multiple myeloma.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll focus further on studies presented at the 2020 ASH Annual Meeting & Exposition, including findings on the use of whole-genome sequencing to trace the origins of a blood cancer; stem cell transplant for older patients with myelodysplastic syndromes; and a triplet therapy for relapsed and refractory multiple myeloma.

The 2020 ASH Annual Meeting & Exposition, held in a virtual format this year, begins today. We're featuring three studies on the podcast this week from the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The 2020 ASH Annual Meeting & Exposition, held in a virtual format this year, begins today. We're featuring three studies on the podcast this week from the meeting.

As COVID-19 infection rates again spike around the nation, this week, we're looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.

Coverage of stories discussed this week on ascopost.com:

Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer

Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> As COVID-19 infection rates again spike around the nation, this week, we're looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.

As COVID-19 infection rates again spike around the nation, this week, we're looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.

Coverage of stories discussed this week on ascopost.com:

Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer

Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

As COVID-19 infection rates again spike around the nation, this week, we're looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.

Coverage of stories discussed this week on ascopost.com:

Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer

Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer

As COVID-19 infection rates again spike around the nation, this week, we're looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.

Coverage of stories discussed this week on ascopost.com:

Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer

Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic